Browse SOD2

Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion matrix.
Domain PF02777 Iron/manganese superoxide dismutases
PF00081 Iron/manganese superoxide dismutases
Function

Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0000303 response to superoxide
GO:0000305 response to oxygen radical
GO:0001306 age-dependent response to oxidative stress
GO:0001315 age-dependent response to reactive oxygen species
GO:0001836 release of cytochrome c from mitochondria
GO:0001976 neurological system process involved in regulation of systemic arterial blood pressure
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0003044 regulation of systemic arterial blood pressure mediated by a chemical signal
GO:0003068 regulation of systemic arterial blood pressure by acetylcholine
GO:0003069 vasodilation by acetylcholine involved in regulation of systemic arterial blood pressure
GO:0003070 regulation of systemic arterial blood pressure by neurotransmitter
GO:0003073 regulation of systemic arterial blood pressure
GO:0003085 negative regulation of systemic arterial blood pressure
GO:0006801 superoxide metabolic process
GO:0006979 response to oxidative stress
GO:0007568 aging
GO:0007571 age-dependent general metabolic decline
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0008631 intrinsic apoptotic signaling pathway in response to oxidative stress
GO:0008637 apoptotic mitochondrial changes
GO:0009636 response to toxic substance
GO:0010035 response to inorganic substance
GO:0019430 removal of superoxide radicals
GO:0032364 oxygen homeostasis
GO:0033483 gas homeostasis
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0035150 regulation of tube size
GO:0036473 cell death in response to oxidative stress
GO:0042311 vasodilation
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0045776 negative regulation of blood pressure
GO:0050880 regulation of blood vessel size
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0051402 neuron apoptotic process
GO:0070997 neuron death
GO:0071450 cellular response to oxygen radical
GO:0071451 cellular response to superoxide
GO:0072593 reactive oxygen species metabolic process
GO:0090066 regulation of anatomical structure size
GO:0097193 intrinsic apoptotic signaling pathway
GO:0098754 detoxification
GO:0098869 cellular oxidant detoxification
GO:1900407 regulation of cellular response to oxidative stress
GO:1900408 negative regulation of cellular response to oxidative stress
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1902175 regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1902176 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1902532 negative regulation of intracellular signal transduction
GO:1902882 regulation of response to oxidative stress
GO:1902883 negative regulation of response to oxidative stress
GO:1903201 regulation of oxidative stress-induced cell death
GO:1903202 negative regulation of oxidative stress-induced cell death
GO:1990748 cellular detoxification
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0004784 superoxide dismutase activity
GO:0016209 antioxidant activity
GO:0016721 oxidoreductase activity, acting on superoxide radicals as acceptor
GO:0030145 manganese ion binding
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa04068 FoxO signaling pathway
hsa04146 Peroxisome
Reactome R-HSA-2262752: Cellular responses to stress
R-HSA-8862803: Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
R-HSA-3299685: Detoxification of Reactive Oxygen Species
R-HSA-1643685: Disease
R-HSA-8863678: Neurodegenerative Diseases
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SOD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SOD2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.53; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SOD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4740.235
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2630.931
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.640.754
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1370.735
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6250.814
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4790.886
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0780.887
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0620.976
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2160.925
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2680.925
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3530.936
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.180.21
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SOD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.331.22.11
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 596033.326.70.58
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47028.6-28.60.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SOD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SOD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SOD2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SOD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SOD2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SOD2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSOD2
Namesuperoxide dismutase 2, mitochondrial
Aliases MNSOD; MVCD6; Mn superoxide dismutase; indophenoloxidase B; manganese-containing superoxide dismutase; manga ......
Chromosomal Location6q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SOD2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SOD2.
ID Name Drug Type Targets #Targets
DB03297Benzylsulfinic AcidSmall MoleculeCMA1, HPN, SOD23
DB044363-FluorotyrosineSmall MoleculeSOD21